Share Name Share Symbol Market Type Share ISIN Share Description
Targovax Ord LSE:0RIS London Ordinary Share NO0010689326 TARGOVAX ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +NOK0.00 +0.00% NOK15.98 NOK0.00 NOK0.00 - - - 0 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0.00

Targovax ASA: Fourth Quarter and Full Year 2018 Results

14/02/2019 7:11am

PR Newswire (US)

Targovax Ord (LSE:0RIS)
Historical Stock Chart

2 Months : From Jan 2019 to Mar 2019

Click Here for more Targovax Ord Charts.

OSLO, Norway, Feb. 14, 2019  /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its fourth quarter and full year 2018 results.

A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET (details below).


  • In October, the Company reported the full data set from the TG01 trial in resected pancreatic cancer. The trial showed six months improvement in median overall survival (mOS) data over comparable historical control trials and RAS-specific immune activation in 94% of patients
  • In October, the Company hosted a Key Opinion Leader Symposium on oncolytic viruses in New York City, with speakers from Memorial Sloan Kettering Cancer Centre presenting an overview of the oncolytic virus space and encouraging interim data from the ONCOS-102 trial in CPI refractory advanced melanoma


  • In January 2019, Targovax announced that the European Patent Office has granted a European Patent which protects Targovax' mutant-RAS specific neoantigen peptides, mutant RAS specific T-cells and vaccines TG01 and TG02, for the treatment of cancer in combination with chemotherapies. This extends the IP protection of TG01 and TG02 into 2034
  • In February 2019, Targovax announced that the first patient has been treated in the dose expansion cohort of the ONCOS-102 trial in melanoma

Øystein Soug, CEO commented: "2018 was the year when we really started to see data read-outs from our two immune activator programs. ONCOS showed the first signs of efficacy in combination trials with both check-point inhibitors and chemotherapy. TG became the first therapeutic cancer vaccine to clinically demonstrate T-cell activation towards a driver mutation, mutant RAS, combined with a clear signal of survival benefit in resected pancreatic cancer patients. We now look forward towards 2019 and 2020 as we continue to progress our clinical program and unlock the full potential of both of these platforms

The presentation will take place at 10:00 CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo
The presentation will also be webcast live and can be accessed here.

Reporting material

TRVX 4Q18 report

TRVX 4Q18 presentation

The quarterly report and presentation are also available at the website

For further information, please contact:
Renate Birkeli,
Investor Relations
Phone: +47-922-61-624

Media and IR enquires:

Andreas Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773

This information was brought to you by Cision,c2740751

The following files are available for download:

TRVX 4Q18 presentation

TRVX 4Q18 report

Copyright 2019 PR Newswire

1 Year Targovax Ord Chart

1 Year Targovax Ord Chart

1 Month Targovax Ord Chart

1 Month Targovax Ord Chart
Your Recent History
Targovax O..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190320 16:35:31